Intel's integrated graphics are getting better and better leaving AMD with very little to offer now except price.
The kind of bounce you get when a gap is filled, from 27.96 on Jun 12th 2014, as I predicted last week
Jun 13, 2014 29.75 30.06 29.56 29.87 122,194,300 29.06
Jun 12, 2014 27.86 28.10 27.77 27.96 31,211,400 27.20
The adjusted gap (due to dividends) is actually down to 27.20 so there is still more bounce powder dry :). As I told Marco when he was touting 25 you also have 20 year moving averages lurking around 26 which also will provide further support.
The only people selling are you shorties and quick profit-takers. True Longs are locked and loaded because they know this is a $10-20 stock in the long term. They have been developing this drug for over a decade.
Previous phase failures were due to testing technicalities not because the drug does not work which was pretty obvious to me reading the PRs.
FDA Approval is a cinch and the market is huge for a safe one-shot drug ! You should know by now I only pick winners williamszxz ;-).
It is just stabilizing before the next leg up.Soon there will be analyst upgrades and institutions buying into this.
Give it time, today is just the glorious start on the way to multiple double figures over the coming years. These drugs are for real for both BPH and CANCER !
'Their drugs clearly work for both cancer and BPH and it is just a matter of time before this is proven beyond doubt and their drugs get approved for use. Eventual stock price target, $10.'
In addition, the following advantages of the new drug are highlighted:
Safety profile highly superior to existing treatments. Minimal or no sexual, hormonal or cardiovascular or other debilitating side effects.
Reduced cancer risk in Phase 2 data: U.S. Phase 2 data showing therapeutic effect of fexapotide on prostate cancer. Phase 2 data showed fexapotide treated low grade localized prostate cancer (Gleason 3+3 or less) had statistically significant less progression compared to controls. By comparison, some commonly used older approved BPH treatments have been linked to increased cancer risk.
Enhanced compliance and patient convenience compared to oral medications. Fexapotide is given as a single painless office treatment injectable. Older approved oral medications generally involve daily pills intended for the rest of the patient’s life.
Cancer next ;-)
There are decades worth of x86 games that could either be ported to a mobile interface or used as is in desktop mode with remote keyboards/mouses or just docking the phone into a big screen interface. The possibilities are endless and that is just with games, How many popular business/scientific x86 applications are there that are not on Android or Ios ? MSFT are truly losing out on utilizing the popular smartphone format by not taking the path of least resistance of using its vast legacy software and instead trying to copy others after that horse has already bolted. They should go flat out with full windows phones and see where the market leads them as they obviously have little innate aptitude for preempting market needs unlike Google or Apple.
' It is unimaginable MS could fail to leverage such a strategic opportunity. '
The main thing that has been stopping them has been the fear of cannibalism i.e. cheap x86 phones affecting their more expensive tablet/PC software which is why they have waited until that they have failed completely in trying to create new ISA-independent ecosystems in tablets and now phones before falling back on their traditional software base. I think they will take a cautious approach and let 3rd party software porters lead the way but eventually they will find a cheap enough price at which the volume of phones offset that price and fully functional Office will be allowed too on these phones.
Like we have been saying for years it just makes too much sense to activate full fat windows on phones for it not to eventually happen but they are obviously being led by their noses to this point. It shows lack of imagination, planning and excessive fear on their part. It is obvious full windows tablets have not killed PCs and neither will full windows phones. They just have to charge less for greater incremental volume. Apple get a premium for their phone software I don't see why MSFT can't too especially when there is just so much legacy x86 software out there to exploit.
No ARM chip can match Intel on price because Intel is willing to both forgo foundry and even division profits to sell its mobile chips. Unlike all the other pretenders it said it would gain a set marketshare in tablets in one year and then exceeded it. It could do the same in phones if it wanted to but is prepared to play the long game in that.
lol he's never been right with his bizarre straw-man obsession with capex and the pps is still miles from his forecast. Mobility revenue/profits has never moved this stock and is rightly seen as an investment in the future as were the first server chips. Win10 will provide a boost for PC sales and the reason it will is because it will introduce a new Windows o/s whose support expiry date is well into the future unlike Win 7/8.